Loading...
Loading...

Bendamustine/Rituximab as Induction Therapy in MCL

Targeted Oncology
Subscribers 2,310
46

Report Video

Found this content disturbing or inciting religious hatred ? email us along with this video url.

[email protected]

Embed Video

Loading...
Published on Dec 09, 2019 at 12:12 am

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Sitting Alone ?

.... Show More